| Efficacy of nivolumab and pembrolizumab in patients with advanced non–small-cell lung cancer needing treatment interruption because of adverse events: a retrospective … D Ksienski, ES Wai, N Croteau, L Fiorino, E Brooks, Z Poonja, D Fenton, ... Clinical lung cancer 20 (1), e97-e106, 2019 | 81 | 2019 |
| Sex differences in presentation and outcome after an acute transient or minor neurologic event YX Amy, AM Penn, ML Lesperance, NS Croteau, RF Balshaw, K Votova, ... JAMA neurology 76 (8), 962-968, 2019 | 58 | 2019 |
| Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice D Ksienski, ES Wai, N Croteau, AT Freeman, A Chan, L Fiorino, ... Lung Cancer 133, 110-116, 2019 | 47 | 2019 |
| Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression … D Ksienski, ES Wai, D Alex, NS Croteau, AT Freeman, A Chan, ... Translational lung cancer research 10 (1), 355, 2021 | 31 | 2021 |
| Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab D Ksienski, ES Wai, NS Croteau, AT Freeman, A Chan, L Fiorino, ... Journal of Geriatric Oncology 11 (5), 807-813, 2020 | 23 | 2020 |
| Differential proteomics for distinguishing ischemic stroke from controls: a pilot study of the SpecTRA project AM Penn, V Saly, A Trivedi, ML Lesperance, K Votova, AM Jackson, ... Translational stroke research 9, 590-599, 2018 | 17 | 2018 |
| Validation of a proteomic biomarker panel to diagnose minor-stroke and transient ischaemic attack: phase 2 of SpecTRA, a large scale translational study AM Penn, MB Bibok, VK Saly, SB Coutts, ML Lesperance, RF Balshaw, ... Biomarkers 23 (8), 793-803, 2018 | 17 | 2018 |
| Verification of a proteomic biomarker panel to diagnose minor stroke and transient ischaemic attack: phase 1 of SpecTRA, a large scale translational study AM Penn, MB Bibok, VK Saly, SB Coutts, ML Lesperance, RF Balshaw, ... Biomarkers 23 (4), 392-405, 2018 | 17 | 2018 |
| White matter hyperintensity volume influences symptoms in patients presenting with minor neurological deficits C Zerna, AYX Yu, ZM Hong, AM Penn, ML Lesperance, NS Croteau, ... Stroke 51 (2), 409-415, 2020 | 10 | 2020 |
| Acquisition of L2 Japanese WH questions: Evidence of phonological contiguity and non-shallow structures J Archibald, N Croteau Second Language Research 37 (4), 649-679, 2021 | 8 | 2021 |
| Individualized prescribing portraits to reduce inappropriate initiation of opioid analgesics to opioid naïve patients in primary care: Protocol for a randomized controlled trial J Klimas, MA Hamilton, G Carney, IR Cooper, NS Croteau, H Dong, ... Contemporary Clinical Trials 107, 106462, 2021 | 8 | 2021 |
| Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab AT Freeman, M Lesperance, ES Wai, NS Croteau, L Fiorino, G Geller, ... Current Oncology 27 (2), 76-82, 2020 | 8 | 2020 |
| Systolic blood pressure as a predictor of transient ischemic attack/minor stroke in emergency department patients under age 80: a prospective cohort study AM Penn, NS Croteau, K Votova, C Sedgwick, RF Balshaw, SB Coutts, ... BMC neurology 19, 1-10, 2019 | 6 | 2019 |
| Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab D Ksienski, PT Truong, NS Croteau, A Chan, E Sonke, T Patterson, ... Journal of Geriatric Oncology 13 (2), 220-227, 2022 | 5 | 2022 |
| Survival outcomes following discontinuation of ipilimumab and nivolumab for advanced melanoma in a population-based cohort D Ksienski, PT Truong, ES Wai, NS Croteau, A Chan, T Patterson, ... Clinical Oncology 33 (12), e561-e569, 2021 | 5 | 2021 |
| 27-gene Immuno-Oncology (IO) score is associated with efficacy of checkpoint immunotherapy in advanced NSCLC: a retrospective BC cancer study DL Saltman, MG Varga, TJ Nielsen, NS Croteau, HM Lockyer, AL Jain, ... Clinical Lung Cancer 24 (2), 137-144, 2023 | 3 | 2023 |
| Characteristics and incidence of opioid analgesic initiations to opioid naïve patients in a Canadian primary care setting J Klimas, MA Hamilton, G Carney, IR Cooper, NS Croteau, H Dong, ... Canadian Journal of Addiction 13 (1), 43-50, 2022 | 3 | 2022 |
| Reducing time-to-unit among patients referred to an outpatient stroke assessment unit with a novel triage process: a prospective cohort study MB Bibok, K Votova, RF Balshaw, ML Lesperance, NS Croteau, A Trivedi, ... BMC Health Services Research 18, 1-9, 2018 | 3 | 2018 |
| Treatment Outcomes of Low-grade Lymphoma of the Orbit CL Holloway, T Pickles, NS Croteau, ES Wai Clinical Oncology 34 (7), E298-E304, 2022 | 2 | 2022 |
| Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice D Ksienski, PT Truong, NS Croteau, A Chan, E Sonke, T Patterson, ... Cureus 13 (11), 2021 | 1 | 2021 |
